Literature DB >> 23982754

Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase 2.

Cristina Antonella Nadalutti1, Ilma Rita Korponay-Szabo, Katri Kaukinen, Martin Griffin, Markku Mäki, Katri Lindfors.   

Abstract

We have recently found that celiac disease patient serum-derived autoantibodies targeted against transglutaminase 2 interfere with several steps of angiogenesis, including endothelial sprouting and migration, though the mechanism involved remained to be fully characterized. This study now investigated the processes underlying the antiangiogenic effects exerted by celiac disease patient antibodies on endothelial cells, with particular regard to the adhesion, migration, and polarization signaling pathway. We observed that celiac IgA reduced endothelial cell numbers by affecting adhesion without increasing apoptosis. Endothelial cells in the presence of celiac IgA showed weak attachment, a high susceptibility to detach from fibronectin, and a disorganized extracellular matrix due to a reduction of protein cross-links. Furthermore, celiac patient IgA led to secretion of active transglutaminase 2 from endothelial cells into the culture supernatants. Additionally, cell surface transglutaminase 2 mediated integrin clustering in the presence of celiac IgA was coupled to augmented expression of β1-integrin. We also observed that celiac patient IgA-treated endothelial cells had migratory defects and a less polarized phenotype when compared to control groups, and this was associated with the RhoA signaling pathway. These biological effects mediated by celiac IgA on endothelial cells were partially influenced but not completely abolished by R281, an irreversible extracellular transglutaminase 2 enzymatic activity inhibitor. Taken together, our results imply that celiac patient IgA antibodies disturb the extracellular protein cross-linking function of transglutaminase 2, thus altering cell-extracellular matrix interactions and thereby affecting endothelial cell adhesion, polarization, and motility.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23982754     DOI: 10.1007/s00018-013-1455-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  36 in total

1.  Activation of transglutaminase type 2 for aortic wall protection in a rat abdominal aortic aneurysm formation.

Authors:  Takashi Munezane; Tomomi Hasegawa; Akiko Tanaka; Kenji Okada; Yutaka Okita
Journal:  J Vasc Surg       Date:  2010-07-07       Impact factor: 4.268

2.  Vinculin--a dynamic regulator of cell adhesion.

Authors:  Kris A Demali
Journal:  Trends Biochem Sci       Date:  2004-11       Impact factor: 13.807

3.  The role of TG2 in ECV304-related vasculogenic mimicry.

Authors:  Richard A Jones; Zhuo Wang; Shakthi Dookie; Martin Griffin
Journal:  Amino Acids       Date:  2012-01-10       Impact factor: 3.520

4.  Cell surface transglutaminase promotes RhoA activation via integrin clustering and suppression of the Src-p190RhoGAP signaling pathway.

Authors:  Anna Janiak; Evgeny A Zemskov; Alexey M Belkin
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

5.  Altered small-bowel mucosal vascular network in untreated coeliac disease.

Authors:  Essi Myrsky; Mari Syrjänen; Ilma R Korponay-Szabo; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423

6.  Autoantibodies to tissue transglutaminase as predictors of celiac disease.

Authors:  W Dieterich; E Laag; H Schöpper; U Volta; A Ferguson; H Gillett; E O Riecken; D Schuppan
Journal:  Gastroenterology       Date:  1998-12       Impact factor: 22.682

7.  Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies.

Authors:  Sergio Caja; Essi Myrsky; Ilma R Korponay-Szabo; Cristina Nadalutti; Ana-Marija Sulic; Miha Lavric; Daniele Sblattero; Roberto Marzari; Russell Collighan; Alexandre Mongeot; Martin Griffin; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Scand J Gastroenterol       Date:  2010-04       Impact factor: 2.423

8.  Transglutaminase activity regulates osteoblast differentiation and matrix mineralization in MC3T3-E1 osteoblast cultures.

Authors:  Hadil F Al-Jallad; Yukiko Nakano; Jeff L Y Chen; Erin McMillan; Céline Lefebvre; Mari T Kaartinen
Journal:  Matrix Biol       Date:  2006-02-15       Impact factor: 11.583

9.  Matrix changes induced by transglutaminase 2 lead to inhibition of angiogenesis and tumor growth.

Authors:  R A Jones; P Kotsakis; T S Johnson; D Y S Chau; S Ali; G Melino; M Griffin
Journal:  Cell Death Differ       Date:  2005-11-18       Impact factor: 15.828

10.  Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.

Authors:  Rasmus Iversen; Roberto Di Niro; Jorunn Stamnaes; Knut E A Lundin; Patrick C Wilson; Ludvig M Sollid
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

View more
  8 in total

Review 1.  Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease.

Authors:  Stefania Martucciello; Gaetana Paolella; Carla Esposito; Marilena Lepretti; Ivana Caputo
Journal:  Cell Mol Life Sci       Date:  2018-08-22       Impact factor: 9.261

2.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

3.  Novel genetic risk variants for pediatric celiac disease.

Authors:  Angeliki Balasopoulou; Biljana Stanković; Angeliki Panagiotara; Gordana Nikčevic; Brock A Peters; Anne John; Effrosyni Mendrinou; Apostolos Stratopoulos; Aigli Ioanna Legaki; Vasiliki Stathakopoulou; Aristoniki Tsolia; Nikolaos Govaris; Sofia Govari; Zoi Zagoriti; Konstantinos Poulas; Maria Kanariou; Nikki Constantinidou; Maro Krini; Kleopatra Spanou; Nedeljko Radlovic; Bassam R Ali; Joseph Borg; Radoje Drmanac; George Chrousos; Sonja Pavlovic; Eleftheria Roma; Branka Zukic; George P Patrinos; Theodora Katsila
Journal:  Hum Genomics       Date:  2016-10-24       Impact factor: 4.639

Review 4.  Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death.

Authors:  H Tatsukawa; Y Furutani; K Hitomi; S Kojima
Journal:  Cell Death Dis       Date:  2016-06-02       Impact factor: 8.469

5.  Transglutaminase 2 in human diseases.

Authors:  Zsuzsa Szondy; Ilma Korponay-Szabó; Robert Király; Zsolt Sarang; Gregory J Tsay
Journal:  Biomedicine (Taipei)       Date:  2017-08-25

6.  Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor.

Authors:  Zhuo Wang; Daniel J Stuckey; Colin E Murdoch; Patrizia Camelliti; Gregory Y H Lip; Martin Griffin
Journal:  Cell Death Dis       Date:  2018-04-27       Impact factor: 8.469

Review 7.  Interplay between Type 2 Transglutaminase (TG2), Gliadin Peptide 31-43 and Anti-TG2 Antibodies in Celiac Disease.

Authors:  Stefania Martucciello; Silvia Sposito; Carla Esposito; Gaetana Paolella; Ivana Caputo
Journal:  Int J Mol Sci       Date:  2020-05-23       Impact factor: 5.923

Review 8.  Transglutaminase 2 and Transglutaminase 2 Autoantibodies in Celiac Disease: a Review.

Authors:  Tiina Rauhavirta; Minna Hietikko; Teea Salmi; Katri Lindfors
Journal:  Clin Rev Allergy Immunol       Date:  2019-08       Impact factor: 10.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.